AnaptysBio, Inc.
dostarlimab
untreated TN40 or stage III dMMR/ MSI-H resectable colon cancer
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for dostarlimab in untreated TN40 or stage III dMMR/ MSI-H resectable colon cancer are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Data expected in 2028”